Tags : Non-Muscle Invasive Bladder Cancer

Merck & Co’s Keytruda (pembrolizumab) Receives the US FDA’s Approval

Shots: The approval is based on KEYNOTE-057 (NCT02625961) study involves assessing of Keytruda (200 mg, q3w) in 96 patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with/out papillary tumors who are ineligible for or have elected not to undergo cystectomy The study resulted in median follow-up time 28 mos., […]Read More